CH Biotech R&D Co., Ltd. (TPE:6534)

Augmedix Revenue

CH Biotech R&D had revenue of 853.66M TWD in the quarter ending March 31, 2025, with 3.50% growth. This brings the company's revenue in the last twelve months to 1.66B, up 8.18% year-over-year. In the year 2024, CH Biotech R&D had annual revenue of 1.64B with 7.98% growth.

• Revenue (ttm): 1.66B
• Revenue Growth: +8.18%
• P/S Ratio: 5.69
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 9.47B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	1.64B	120.91M	7.98%
Dec 31, 2023	1.51B	80.71M	5.63%
Dec 31, 2022	1.43B	415.61M	40.81%
Dec 31, 2021	1.02B	316.32M	45.05%
Dec 31, 2020	702.19M	-138.49M	-16.47%